Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Level 5 - mechanism / opinion, no new human data
Clinical practice guideline and expert panel recommendations
PubMed 26992838 · doi:10.1016/j.ophtha.2016.01.058
What was done
The American Academy of Ophthalmology updated its clinical recommendations for chloroquine (CQ) and hydroxychloroquine (HCQ) retinopathy screening based on revised evidence concerning toxicity prevalence, risk factors, fundus distribution patterns, and diagnostic modality effectiveness.
What was found
The panel recommended a maximum daily HCQ dose of ≤5.0 mg/kg real weight and CQ dose of ≤2.3 mg/kg real weight. At recommended doses, cumulative toxicity risk is <1% up to 5 years, <2% up to 10 years, and approximately 20% after 20 years (with a subsequent 4% annual risk). Key risk factors identified include high dose, long duration, renal disease, and concurrent tamoxifen use. Asian patients frequently exhibit an extramacular pattern of damage. Recommended primary screening includes baseline evaluation followed by annual screening after 5 years using automated visual fields and spectral-domain optical coherence tomography (SD-OCT).
Why it matters
This revised guideline established actual body weight rather than ideal weight as the standard for HCQ dosing and defined multimodal objective screening protocols to detect irreversible retinopathy before central vision loss occurs.
Limits
As an abstract of a clinical practice guideline, specific study sample sizes, formal evidence grading, and systematic search methodologies are not reported. Chloroquine recommendations are derived from older literature rather than contemporary demographic data.
Cited by
- supports Prolonged use of hydroxychloroquine can cause retinopathy.